134 related articles for article (PubMed ID: 15509119)
1. Oral ascorbic acid as adjuvant to epoetin alfa in hemodialysis patients with hyperferritinemia.
Nguyen TV
Am J Health Syst Pharm; 2004 Oct; 61(19):2007-8. PubMed ID: 15509119
[No Abstract] [Full Text] [Related]
2. Comment on "Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?".
Coyne DW; Trout JR; Kapoian T
Nat Clin Pract Nephrol; 2008 Oct; 4(10):E1; discussion E2. PubMed ID: 18818660
[No Abstract] [Full Text] [Related]
3. Is intravenous ascorbic acid an effective and safe option for increasing hemoglobin levels in patients with a hyporesponse to epoetin alfa?
Kear TM
Nephrol Nurs J; 2012; 39(2):137-40. PubMed ID: 22690447
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.
Berns JS; Mosenkis A
Hemodial Int; 2005 Jan; 9(1):7-22. PubMed ID: 16191049
[TBL] [Abstract][Full Text] [Related]
6. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
7. Epoetin dosing and dialysis facility ownership.
Regidor DL; Kalantar-Zadeh K; Kovesdy CP
JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
[No Abstract] [Full Text] [Related]
8. [Current recommendations for the treatment of iron deficiency anemia].
Schaefer RM; Huch R; Krafft A;
Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
[TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid use in hyporesponders to Epoetin alfa.
Gibbs MA
Nephrol Nurs J; 2000 Aug; 27(4):413-5. PubMed ID: 11276634
[TBL] [Abstract][Full Text] [Related]
10. Ace inhibitors and erythropoietin response in hemodialysis patients.
Ertürk S
Am J Kidney Dis; 2000 Oct; 36(4):880. PubMed ID: 11007696
[No Abstract] [Full Text] [Related]
11. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
Driver PS
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
[TBL] [Abstract][Full Text] [Related]
13. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
14. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit.
Macdougall IC; Chandler G; Elston O; Harchowal J
Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S40-6. PubMed ID: 10516375
[TBL] [Abstract][Full Text] [Related]
16. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
18. Use of epoetin in chronic renal failure.
Coyne DW
JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
[No Abstract] [Full Text] [Related]
19. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Więcek A; Ahmed I; Scigalla P; Koytchev R
Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
[TBL] [Abstract][Full Text] [Related]
20. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
